ALK and non-small cell lung carcinoma: Pembrolizumab is indicated for the first-line treatment of any histological type of metastatic NSCLC if the tumor is highly positive for PD-L1 expression and negative for EGFR and ALK-1 genetic aberrations [8,27,28].